2-chlorodeoxyadenosine Therapy in Waldenstroms Macroglobulinemia
(1994) Nouvelle Revue Francaise d’Hematologie - Journal of Experimental and Clinical Hematology — Vol. 36, n° 4, p. 317-320 (1994)
Files
No attached file found for this publication.
Details
- Authors
- Abstract
- Despite some encouraging first results, experience with 2-chlorodeoxyndenosine (CdA) in the treatment of Waldenstrom's macroglobulinaemia (WM) has not as yet been very extensive. The present paper reports a clinical trial of the use of CdA in 18 patients having previously treated (n = 13) or untreated (n = 5) WM. CdA was administered by continuous intravenous infusion at a dose of 4 mg/m(2)/day for 7 days (5 patients) or as 2-h intravenous infusions at. a dose of 5.6 mg/m(2)/day for 5 days (13 patients). Partial response was obtained in 7 cases. In this small series, no correlation could be found between response to CdA and patient characteristics at inclusion. During the first course of therapy, grade 4 neutropenia (< 0.5 x 10(9)/L) and thrombocytopenia (< 25 x 10(9)/L) developed in respectively 4 and 6 cases. In comparison with earlier reports haematological toxicity was more severe and the overall response rare lower in the present series of patients.
- Affiliations
Citations
Delannoy, A., Ferrant, A., Martiat, P., Bosly, A., Zenebergh, A., & Michaux, JL. (1994). 2-chlorodeoxyadenosine Therapy in Waldenstroms Macroglobulinemia. Nouvelle Revue Francaise d’Hematologie - Journal of Experimental and Clinical Hematology, 36(4), 317-320. https://hdl.handle.net/2078.5/90115 (Original work published 1994)